Zobrazeno 1 - 10
of 335
pro vyhledávání: '"cytokine release syndrome (CRS)"'
Autor:
Meng Su, Luoquan Chen, Li Xie, Aurore Fleurie, Renaud Jonquieres, Qing Cao, Benshang Li, Ji Liang, Yanjing Tang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
CAR-T cell therapy is a revolutionary new treatment for hematological malignancies, but it can also result in significant adverse effects, with cytokine release syndrome (CRS) being the most common and potentially life-threatening. The identification
Externí odkaz:
https://doaj.org/article/6647b660b405428284be90459647350f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multipl
Externí odkaz:
https://doaj.org/article/00ef79012c4c4dbe9f0470b81faa2a40
Autor:
Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/cd859f76c53d447c8fd135cb8b7ac6da
Autor:
Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-17 (2023)
Abstract Background Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 invest
Externí odkaz:
https://doaj.org/article/26e8df351a78481d84b79ca3e21d57c8
Autor:
Baitao Dou, Shihui Ren, Ling Qiu, Xupai Zhang, Nan Zhang, Jiao Cai, Dan Chen, Qian Zhang, Hao Yao, Fangyi Fan
Publikováno v:
Frontiers in Medicine, Vol 10 (2024)
BackgroundChimeric antigen receptor T (CAR-T) cell immunotherapy is becoming one of the most promising treatments for hematological malignancies, however, complications such as cytokine release syndrome (CRS) seriously threaten the lives of patients.
Externí odkaz:
https://doaj.org/article/816e30924f1c4e6394fafe663d5100ce
Autor:
Zhenyu Wei, Jiayu Xu, Chengkui Zhao, Min Zhang, Nan Xu, Liqing Kang, Xiaoyan Lou, Lei Yu, Weixing Feng
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionCAR-T cell therapy is a novel approach in the treatment of hematological tumors. However, it is associated with life-threatening side effects, such as the severe cytokine release syndrome (sCRS). Therefore, predicting the occurrence and d
Externí odkaz:
https://doaj.org/article/a54fee77364448639b4f16981b17bb89
Autor:
Marina Caballero-Bellón, Anna Alonso-Saladrigues, Sara Bobillo-Perez, Anna Faura, Laura Arqués, Cristina Rivera, Albert Català, Jose Luis Dapena, Susana Rives, Iolanda Jordan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionChimeric antigen receptor (CAR)T-cell CD19 therapy is an effective treatment for relapsed/refractory B-cell acute lymphoblastic leukemia. It can be associated with life-threatening toxicities which often require PICU admission. Purpose: t
Externí odkaz:
https://doaj.org/article/98ca342b9c1b44b8aac013f40ff44801
Autor:
Vassilis Genoud, Denis Migliorini
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Chimeric antigen receptor (CAR) T cell therapy represents a scientific breakthrough in the treatment of advanced hematological malignancies. It relies on cell engineering to direct the powerful cytotoxic T-cell activity toward tumor cells. Neverthele
Externí odkaz:
https://doaj.org/article/afad2042b6c7481dbd112536677b661d
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-23 (2021)
Abstract Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the US Food and Drug Administration (
Externí odkaz:
https://doaj.org/article/84985de6e1064d9e8565a628289e86e7
Autor:
Gabrielle Leclercq, Nathalie Steinhoff, Hélène Haegel, Donata De Marco, Marina Bacac, Christian Klein
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
T cell engaging therapies, like CAR-T cells and T cell engagers, redirect T cells toward tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing. T cell receptor or CAR-T downstream signaling trig
Externí odkaz:
https://doaj.org/article/78ca37b7b7384732b4b43c73e29d596c